GSK widens the mar­ket for Ze­ju­la as FDA signs off on the PARP in­hibitor for use in ovar­i­an can­cer pa­tients with­out BR­CA mu­ta­tions

GSK has vast­ly ex­pand­ed its mar­ket for can­cer ther­a­py Ze­ju­la — the crown jew­el at the heart of its $5 bil­lion ac­qui­si­tion of Tesaro — by win­ning FDA ap­proval for the drug in a large sub­set of pa­tients with ovar­i­an can­cer.

The ap­proval comes for women with ad­vanced ep­ithe­lial ovar­i­an, fal­lop­i­an tube, or pri­ma­ry peri­toneal can­cer who ex­pe­ri­enced a com­plete or par­tial re­sponse to first-line plat­inum-based chemother­a­py — ac­count­ing for ap­prox­i­mate­ly 80% of all ovar­i­an can­cer pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.